anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A substantial number of critically ill patients experience persistent organ failure leading to chronic critical illness (CCI). The majority of these patients die within a year, and many survivors must cope with long-term physical and cognitive limitations that are often severe. Survival with severe physical and cognitive dysfunction is a significant clinical, emotional, and economic burden in this population, but little is known about which patients are at highest risk for physical and cognitive dysfunction. Moreover, although long-term mortality in CCI can be reliably estimated with a validated mortality prediction model, there is currently no validated method to predict long-term functional disability for purposes of shared decision-making and resource planning. In order to address these gaps in knowledge, the investigators will conduct a multi-center prospective cohort study that measures clinical and premorbid risk factors for long-term physical and cognitive dysfunction in CCI. Using these risk factors, the investigators will construct a multi-outcome prognostic model for survival with severe physical or cognitive dysfunction to facilitate shared decision-making and resource planning. Additionally, the investigators will identify independent social and economic variables that are risk factors for long-term survival and functional disability.
Participants (ntotal=50) will be men and women, ages 45-60. All interested participants will first complete a structured telephone interview in order to assess eligibility.

The study will begin with filling out questionnaires, as well as an online session to complete some tasks. You will then be randomly assigned to take either an anti-inflammatory medication (naproxen) or placebo (inactive substance) to take twice daily everyday for the following two weeks. You will also be contacted by text message to remind you to take your pills, to ask if you have taken your pills, and to send you a link to fill out questionnaires once daily. After the two weeks are over, you will again complete questionnaires and the online study session with tasks. Finally, two weeks after the second session, you will receive an email to fill out questionnaires online.
PROBLEM TO BE SOLVED: To obtain a solid preparation composition having a high quality and prevented in degradation to stabilize the composition with time by compounding a vitamin B1 derivative with a specific stabilizer. SOLUTION: This solid preparation composition contains a vitamin B1 derivative (especially preferably a vitamin B1 derivative having a disulfide bond) and further starch and calcium biphoshate as stabilizers. The calcium biphosphate is compounded in an amount of 0.01-10 pts.wt. per pt.wt. of the vitamin B1 derivative. The starch is also compounded in an amount of 0.01-10 pts.wt. per pt.wt. of the vitamin B1 derivative. The vitamin B1 derivative is e.g. bisibuthiamine, thiamine disulfide, bisbentiamine, etc., especially the bisbentiamine having a remarkable stabilization effect. The starch is preferably corn starch or potato starch.
Normal weight subjects (body mass index 20-25) will be given propofol during induction of general anesthesia. Plasma samples will be collected over time to ascertain propofol plasma concentration.
FIELD: hygiene.SUBSTANCE: group of inventions relates to the field of human life support, namely to oral hygiene and dental cleaning. Proposed powder composition for occupational hygiene of oral cavity contains sodium bicarbonate, calcium carbonate, a flavouring agent, hydrophilic silicon dioxide and hydrophobic silicon dioxide, wherein the composition contains particles sized 20–50 mcm or 50–90 mcm or 20–90 mcm. To produce composition, wt. %: sodium hydrocarbonate 75-87.5, flavouring 1.0, calcium carbonate 10–23.75, hydrophilic silicon dioxide 0.05–1.0, hydrophobic silicon dioxide 0.2–0.5. Method for preparing the powdered oral hygiene composition involves using sodium bicarbonate, calcium carbonate, a flavouring agent, hydrophilic silicon dioxide and hydrophobic silicon dioxide in said amounts. Sodium bicarbonate, calcium carbonate and flavouring agent are mixed, after which they are ground in a mill. After grinding, the powder mixture is sieved to 20–50 mcm or 50–90 mcm or 20–90 mcm. Hydrophilic silicon dioxide is added to the sifted composition and mixed until homogeneous mass formation, then hydrophobic silicon dioxide is added and mixed to form a mono-particular layer. Obtained powder composition is sifted on a corresponding sieve to remove excess hydrophilic and hydrophobic silicon dioxide. Increased abrasiveness due to introduction of calcium carbonate reduces time of hygienic cleaning of teeth. Improved flowability of the powder composition and antifriction properties provided to it ensure continuous operation of the doctor in the process of occupational hygiene of the oral cavity without distracting it for cleaning the Air Flow apparatus. Separation according to fractions provides optimum use of powder compositions depending on the nature and specificities of the plaque on the patient's teeth. Powder composition with particle size of 20–50 mcm is used to remove soft coating and to enamel teeth, perform cleaning of metal structures and bracket systems; powder composition with particle size of 50–90 mcm removes dense deposit, smell of smoker and coffee lover; powdered composition of 20–90 mcm provides for removal of plaque of medium density.EFFECT: technical result is increased flowability of composition, improved antifriction properties, reduced time for hygienic cleaning of teeth in comparison with prototype.2 cl
A wireless network having two types of nodes, a first sender type node and a second transceiving type node. The network may be used in a medical setting whereby the first type node may be wireless devices that monitor physical parameters of a patient, such as wireless oximeters. The second type node are mobile wireless communicators that, if in transmission range, are adapted to receive data from the wireless devices. After aggregating the received data, each of the node communicators broadcasts its most up to date data onto the network. Any other communicator in the network that is within the broadcast range of a broadcasting communicator would receive the updated data. This makes it possible for communicators that are out of the transmitting range of a wireless device to receive updated data regarding the patient. Each communicator is able to transcive and display data from a variety of wireless devices.
This study will be a 2 arm controlled clinical trial (CCT) comparing usual care to usual care plus MBSR. Participants will be residents of a local inpatient treatment facility for adolescents with serious mental health issues. Outcomes the investigators will measure include mental health status as well as mindfulness. The investigators will also conduct qualitative interviews to assess the personal impact of the intervention on the patients and their families. In order to map and measure cognitive changes during MBSR the investigators will conduct brain imaging using functional magnetic resonance imaging (fMRI) and Event-Related Potential (ERP) recordings. Through this study the investigators will determine if MBSR is helpful to our population.
1330407 X-ray opaque polymethacrylate particles COE LABORATORIES Inc 23 April 1971 [1 May 1970] 11043/71 Heading C3P An X-ray opaque granular polymethacrylate composition comprises finely divided, solid, clear and colourless beads obtained from a suspension polymerization of an alkyl methacrylate, the beads being soluble in liquid methacrylate monomer to form a dough, and at least one organic halide compound comprising at least 50% by weight of bromine or iodine within the beads to impart detectable X-ray opacity thereto, the amount of the organic halide(s) being from 10-40% by weight of the beads. The composition is prepared by dissolving the organic halide(s) in monomeric alkyl methacrylate and polymerizing the monomer in suspension in a non-solvent vehicle in the presence of a macromolecular lyophilic suspending agent present in an amount up to 1% by weight of the vehicle and in the presence of a polymerization catalyst, e.g. benzoyl peroxide. The methacrylate monomer is preferably methyl methacrylate and may be used in conjunction with a comonomer, e.g. styrene, vinyl acetate, vinyl chloride, vinylidene chloride or ethylene glycol dimethacrylate. The suspension vehicle may be, for example, water, and the suspending agent may be a mixture of starch and carboxymethyl cellulose. Useful organic halides include tetrabromoethane, dibromopropanol, tetrabromobisphenol A, bromoform, p-dibromobenzene, dibromoethane, ethyl iodide, p-iodotoluene, 2,4,6-triiodophenol, iodobenzene, 1,3- diiodopropane, dibromoneopentyl glycol, dibromotoluene, bromopyridine, iodopropane and bromo vanillin. There may also be incorporated in the methacrylate monomer used ultra-violet absorbers, dyestuffs and brominated polyisobutylene (to improve impact strength &c.). The polymer beads obtained by the above procedure may be milled with non-toxic, naturally coloured, X-ray opaque pigments to enhance the X-ray opacity and to impart colour characteristic to the beads. Articles formed from the polymer beads can be detected by X-rays when present within the living body. The polymer beads can be admixed with methyl methacrylate monomer to form a dough which is then polymerized with an accelerator and shaped to form a dental prosthetic article; a blend of heavy metal pigment compounds may optionally be included in the admixture.
The Press therapeutic algorithm will be responsible for adjustment of intraoperative interventions based upon standard pressure parameters and will include volumotherapy and administration of vasoactive drugs, with the aim to maintain the desired values of MAP of 65-105 mmHg and CVP 8-12 mmHg. After the desired values of MAP and CVP have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the release of mediators from sensitized mast cells. Cromolyn sodium acts by inhibiting the release of histamine and leukotrienes (SRS-A) from the mast cell. 

Cromolyn sodium has no intrinsic vasoconstrictor, antihistamine, or glucocorticoid activity. 

Cromolyn sodium is poorly absorbed from the gastrointestinal tract. No more than 1% of an administered dose is absorbed by humans after oral administration, the remainder being excreted in the feces. Very little absorption of cromolyn sodium was seen after oral administration of 500 mg by mouth to each of 12 volunteers. From 0.28 to 0.50% of the administered dose was recovered in the first 24 hours of urinary excretion in 3 subjects. The mean urinary excretion of an administered dose over 24 hours in the remaining 9 subjects was 0.45%.
Aim 1 will be to measure bloodflow during exercise of the legs (below the injury). This aim will examine the control of bloodflow and muscle contractions and how it changes after spinal cord injury.
BACKGROUND: To determine the prevalence of HR-HPV in a series of lip SCC from South African patients, using currently accepted HPV-testing methodologies and to define the clinical and histomorphologic features of HPV-associated lip SCC.
METHODS: Fifty SCC of lip and 50 control cases were tested for HR-HPV using p16 and HR-HPV DNA PCR. p16-equivocal/positive and HPV DNA PCR-positive SCC were further evaluated for the expression of HPV-16 and HPV-18 mRNA transcripts using reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) to confirm transcriptionally active HPV.
RESULTS: p16 was positive in 22% (n = 11) and equivocal in 4% (n = 2) of the SCC. One p16-positive case showed positivity for both HPV-16 DNA and HPV-16 E6/E7 mRNA transcripts (HPV prevalence rate of 2%). The HPV-positive case was non-keratinizing and occurred in an 80-year-old female. The two p16-equivocal cases were HR-HPV DNA positive and mRNA PCR negative. p16 was found to have a positive predictive value of 9%.
CONCLUSION: Findings from our cohort of lip SCC suggest that HR-HPV may have an insignificant role in the pathogenesis of SCC at this site. Due to its low ppv, p16 is insufficient to establish HR-HPV infection in SCC of the lip. The combination of p16 and DNA PCR appears to correlate with the presence of transcriptionally active virus. HPV E6/E7 mRNA detection is the gold standard for identifying HR-HPV. mRNA testing is not widely available in sub-Saharan Africa due to technical and financial constraints; however, the test appears to be of great value in p16-equivocal lip SCC.
Blackleg disease, caused by Leptosphaeria spp. fungi, is one of the most important diseases of Brassica napus, responsible for severe yield losses worldwide. Blackleg resistance is controlled by major R genes and minor quantitative trait loci (QTL). Due to the high adaptation ability of the pathogen, R-mediated resistance can be easily broken, while the resistance mediated via QTL is believed to be more durable. Thus, the identification of novel molecular markers linked to blackleg resistance for B. napus breeding programs is essential. In this study, 183 doubled haploid (DH) rapeseed lines were assessed in field conditions for resistance to Leptosphaeria spp. Subsequently, DArTseq-based Genome-Wide Association Study (GWAS) was performed to identify molecular markers linked to blackleg resistance. A total of 133,764 markers (96,121 SilicoDArT and 37,643 SNP) were obtained. Finally, nine SilicoDArT and six SNP molecular markers were associated with plant resistance to Leptosphaeria spp. at the highest significance level, p < 0.001. Importantly, eleven of these fifteen markers were found within ten genes located on chromosomes A06, A07, A08, C02, C03, C06 and C08. Given the immune-related functions of the orthologues of these genes in Arabidopsis thaliana, the identified markers hold great promise for application in rapeseed breeding programs.
PURPOSE: We developed a method to measure the extracellular and intracellular fluid volumes using the kinetics of uric acid in the bodies of Japanese patients undergoing dialysis. In this research, we aimed to assess the prognosis of vascular events using this uric acid kinetic model method.
METHODS: We conducted a retrospective cohort study of 1,298 patients who were undergoing hemodialysis or predilution online hemodiafiltration at the end of December 2019 at 13 institutions in Japan. Information on vascular events was acquired in 2020. Vascular event prognosis was defined as the new incidence of one or more of the following four types of vascular events: myocardial infarction, cerebral infarction, cerebral hemorrhage, or limb amputation. We measured the extracellular fluid volume and intracellular fluid volume after dialysis using the uric acid kinetic model method and determined the association between ECV, ICV, and vascular event risk.
RESULTS: A high extracellular volume was substantially linked to an increased risk of vascular events. In addition, while a crude analysis revealed that a high intracellular volume was associated with a low risk of vascular events, this was not statistically significant after multifactorial adjustment. This result was partly affected by the low measurement accuracy of the serum urea nitrogen level used for the intracellular volume calculation.
CONCLUSIONS: Extracellular volume calculated using the uric acid kinetic model method is a prognostic factor for vascular events in patients undergoing hemodialysis.
This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
Some embodiments of the invention include pseudotyped particles (e.g., pseudo typed exosomes, pseudotyped VSV, and pseudo typed lentiviruses) and modified cells. Other embodiments of the invention include compositions (e.g., pharmaceutical compositions) of pseudotyped particles (e.g., pseudotyped exosomes, pseudotyped VSV, and pseudotyped lentiviruses) and modified cells. Certain embodiments of the invention include methods of making pseudotyped particles (e.g., pseudotyped exosomes, pseudotyped VSV, and pseudotyped lentiviruses) and modified cells. Other embodiments of the invention include methods of administering pseudotyped particles (e.g., pseudotyped exosomes, pseudotyped VSV, and pseudotyped lentiviruses). Further embodiments of the invention include methods of administering pseudotyped particles (e.g., pseudotyped exosomes, pseudotyped VSV, and pseudotyped lentiviruses) to treat diseases (e.g., muscular dystrophy). Additional embodiments of the invention are also discussed herein.
The invention relates to a reactor for continuously generating water with high oxidation potential and high reduction potential. The reactor comprises a positive electrode (7), a negative electrode (5), a cation exchange membrane and insulation housing (8) and an electronic control box (9). The positive electrode and the negative electrode are arranged in inner sides of the length direction of the acid resistant, alkali resistant and high voltage resistant housing. The two electrodes are arranged equidistantly and parallelly. A pipe is injected with water, an end of the pipe is provided for water entering, the other end of the pipe is provided for water discharging. The positive electrode (7) and the negative electrode (5) are connected through the high voltage direct current power supply to form the reactor for continuously generating the water with high oxidation potential and high reduction potential. A plurality of the reactors provided with the positive electrodes, the negative electrodes and the cation exchange membranes can form a sealed connection in series through elbows until the length achieves the desired length; then the positive electrodes and the negative electrodes of all processing units form a parallel connection, which is connected with the direct current power supply to form a composite reactor. With the reactor provided by the present invention, large amount of the water with high oxidation potential and high reduction potential can be generated and provided real timely; the reactor is applicable for meeting the requirement of continuous generation of the water with high oxidation potential and high reduction potential, and can be applicable for the civilian water treatment and the industrial water treatment.
The prevalence of obesity, a major chronic health problem that is an independent risk factor for coronary heart disease (CHD), continues to increase at an alarming rate. Although weight control research has significantly improved short-term treatment success, long-term weight loss maintenance has lagged behind. Research has demonstrated a consistent relationship between self-monitoring eating and physical activity habits and success in weight loss as well as in maintenance of weight loss. However, the methods primarily used for self-monitoring continue to be the paper diary (PD), which is time consuming and burdensome. Moreover, PDs do not permit immediate external feedback to support and motivate the individual. Emerging technologies could improve self-monitoring and weight loss treatment. However, the use of these technological advances, such as a personal digital assistant (PDA), has not been studied in weight loss treatment. The primary aim of this behavioral weight loss treatment study is to determine if self-monitoring of daily eating and physical activity habits using a PDA, with or without a tailored feedback intervention, is superior to using a PD in terms of promoting and maintaining short- and long-term weight loss. Secondary aims include comparing the effect of treatment group assignment on adherence to self-monitoring and on risk factors for CHD (lipids, glucose, insulin, C-reactive protein). We propose to enroll 198 subjects and randomize them to one of three treatment groups that will use different methods to self-monitor eating and physical activity habits: (1) use of the traditional PD with delayed written feedback, (2) use of a PDA with limited feedback on daily targets, or (3) use of a PDA with limited feedback on daily targets plus receive daily, subject-tailored feedback messages via the PDA. The proposed study includes prolonged (24 months) supervision of self-management with three important components: self-monitoring, feedback, and ongoing contact. Subjects will complete assessments at baseline, 6, 12, 18, and 24 months. This innovative study will provide information on the efficacy of combining technological advances with proven behavioral strategies.
Participants will receive Aticaprant 10 milligrams (mg) tablet orally, once daily for 42 days during double-blind (DB) treatment phase in addition to their current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy. Participants who will complete the DB treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study 67953964MDD3003.
<P>PROBLEM TO BE SOLVED: To provide a functional composition having especially excellent immunopotentiating actions by using a material derived from a natural product as a raw material.  <P>SOLUTION: The healthy functional composition is characterized by comprising a mushroom such as Ganoderma amboinense and/or an extract thereof and a lactic acid bacterium and has the especially excellent immunopotentiating actions. Lactobacterium acidophillum n.v. 317/402 (narine bacterium) is preferred as the lactic acid bacterium. A lactic acid bacterium fermentation product such as the narine is a concept included in the category of the lactic acid bacterium. The representative form of the healthy functional composition is a healthy functional food such as a healthy functional beverage.  <P>COPYRIGHT: (C)2004,JPO
Meningioma is one of the most common primary intracranial tumors, accounting for 13% to 26% of all intracranial tumors. Although most meningiomas are benign tumors and can be cured by surgical resection, more than 20% of WHO II (atypical) and about 3% of WHO III meningiomas are more likely to have local recurrence after initial treatment , And the lifetime is poor. The immunotherapy represented by PD-1 has achieved remarkable efficacy in the treatment of solid tumors, but the application of PD-1 in recurrent meningioma is rarely reported. The study found that the expression of PD-L1 mRNA and protein in high-grade meningioma cells increased, and the total number of T cells, including CD4+ and CD8+ cells, was significantly reduced, suggesting an inhibitory tumor immune microenvironment. Recent studies have shown that giving patients anti-PD-1 antibody immunotherapy prior to conventional treatment can improve the pathological response, enable the body to produce an enhanced and sustained anti-tumor immune response, and form a tumor microenvironment conducive to immunotherapy. Therefore, giving PD-1 antibody before surgery is a new idea for the treatment of meningiomas. This project aims to investigate whether patients with recurrent meningioma will change their immune function and prolong survival after preoperative PD-1 antibody treatment. It is planned to use flow cytometry, multiple immunofluorescence histochemistry technology, T cell receptor sequencing, etc to detect the changes in the patient's immune function before and after treatment, observe the pathological remission rate of PD-1 monoclonal antibody neoadjuvant treatment of recurrent meningioma, and identify potential response biomarkers, and conduct in-depth discussions on this treatment plan to further determine the treatment mode Clinical value and specific mechanism of action in order to improve the clinical treatment level of patients with recurrent meningioma.